Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins

Chae, Young Kwang; Valsecchi, Matías E.; Kim, Jong‐Oh; Bianchi, Anabella Lucca; Khemasuwan, Danai; Desai, Ajit; Tester, William J.

doi:10.3109/07357907.2011.616252

Cited by 154 publications

(163 citation statements)

References 46 publications

Supporting

Mentioning

151

Contrasting

Unclassified

Order By: Relevance

“…This finding is consistent with virtually all previously reported data (cancer-specific mortality: HR 0.73, 95% CI 0.59-0.92, P = 0.000; all-cause mortality: HR 0.72, 95% CI 0.58-0.89, P = 0.000). In addition, many articles have confirmed that the use of statins can reduce breast cancer incidence and the risk of recurrence [13,14], thus indicating the wide-ranging protective effects of statins in patients with breast cancer. However, the mechanism for how statins improve the prognosis of patients with cancer differs from that in the cardiovascular field.…”

Section: Discussionmentioning

confidence: 99%

The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis

Liu

Guan

et al. 2017

Breast Cancer Res Treat

View full text Add to dashboard Cite

Purpose Breast cancer is the most common cancer in females and the leading cause of death worldwide. The effects of statins on breast cancer prognosis have long been controversial; thus, it is important to investigate the relationship between statin type, exposure time, and breast cancer prognosis. This study sought to explore the effect of statins, as well as the different effects of statin solubility and variable follow-up times, on breast cancer prognosis.

show abstract

Section: Discussionmentioning

confidence: 99%

The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis

Liu

Guan

et al. 2017

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Based on these observations, GGTI treatment appears as a promising anti-CSC therapy. The use of statins, which inhibit MVA metabolism, reduces the risk of breast cancer recurrence [38,39]. This observation may be linked to the inhibition of CSCs.…”

Section: Discussionmentioning

confidence: 99%

Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target

et al. 2012

View full text Add to dashboard Cite

There is increasing evidence that breast tumors are organized in a hierarchy, with a subpopulation of tumorigenic cancer cells, the cancer stem cells (CSCs), which sustain tumor growth. The characterization of protein networks that govern CSC behavior is paramount to design new therapeutic strategies targeting this subpopulation of cells. We have sought to identify specific molecular pathways of CSCs isolated from 13 different breast cancer cell lines of luminal or basal/mesenchymal subtypes. We compared the gene expression profiling of cancer cells grown in adherent conditions to those of matched tumorsphere cultures. No specific pathway was identified to be commonly regulated in luminal tumorspheres, resulting from a minor CSC enrichment in tumorsphere passages from luminal cell lines. However, in basal/mesenchymal tumorspheres, the enzymes of the mevalonate metabolic pathway were overexpressed compared to those in cognate adherent cells. Inhibition of this pathway with hydroxy-3-methylglutaryl CoA reductase blockers resulted in a reduction of breast CSC independent of inhibition of cholesterol biosynthesis and of protein farnesylation. Further modulation of this metabolic pathway demonstrated that protein geranylgeranylation (GG) is critical to breast CSC maintenance. A small molecule inhibitor of the geranylgeranyl transferase I (GGTI) enzyme reduced the breast CSC subpopulation both in vitro and in primary breast cancer xenografts. We found that the GGTI effect on the CSC subpopulation is mediated by inactivation of Ras homolog family member A (RHOA) and increased accumulation of P27 kip1 in the nucleus. The identification of protein GG as a major contributor to CSC maintenance opens promising perspectives for CSC targeted therapy in basal breast cancer. STEM

show abstract

“…No reduced risk was observed in users of hydrophilic statins. In 703 American women treated for stage II/III breast cancer between 1999 and 2005 and followed until 2008, users of statins (n = 156) had a reduced risk of recurrence in multivariate analysis (HR = 0.40, 95% CI, 0.24-0.67) (Chae, Valsecchi et al 2011). No effect was seen on overall survival.…”

Section: Breast Cancer Epidemiological Studies Showing a Higher Incimentioning

confidence: 89%

Lipoproteins and Cancer

Antalis¹,

Buhman²

2012

Lipoproteins - Role in Health and Diseases

View full text Add to dashboard Cite

Reduced Risk of Breast Cancer Recurrence in Patients Using ACE Inhibitors, ARBs, and/or Statins

Abstract: The use of ACE-inhibitors/ARBs, statins, and the combination of both were all associated with a reduced risk of breast cancer recurrence. This observation should prompt further exploration.

Cited by 154 publications

References 46 publications

The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis

The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis

Mevalonate Metabolism Regulates Basal Breast Cancer Stem Cells and Is a Potential Therapeutic Target

Lipoproteins and Cancer

Contact Info

Product

Resources

About